One of the most repeated claims in psychedelic research is that a single dose produces a durable increase in the personality trait openness, a finding reported across multiple clinical trials and treated as one of the field’s more reliable effects. A new naturalistic study asked a straightforward question: does that effect show up in ordinary first-time users outside a clinical setting, at the doses and circumstances people actually encounter it in. The honest answer, once the statistics are handled properly, is not really, and what small effect remained wasn’t unique to psychedelics.
The study
Researchers followed 102 Berlin university students taking a psychedelic for the first time, compared against 1,066 students who had never used one, over a full year. Personality was measured at the start and end of the period using the Big Five Inventory, the standard framework covering openness, conscientiousness, extraversion, agreeableness, and neuroticism. In the raw, unadjusted comparison, first-time users showed the pattern the clinical literature would predict, a small relative increase in openness and a small decrease in conscientiousness.
What happened when the analysis got rigorous
The researchers then adjusted for age, sex, income, psychiatric diagnosis, and how much other substance use each person already had at baseline, the confounders that could produce an apparent personality shift with nothing to do with the psychedelic itself. Once adjusted, both effects shrank. The openness increase came in at a p-value of 0.06, just short of the conventional significance threshold. The conscientiousness decrease landed right at 0.05, the threshold itself. Neither is a clean positive result on its own, and appropriately, the researchers then corrected for running multiple comparisons at once, the standard and necessary step when a study tests several outcomes and wants to avoid mistaking noise for signal. After that correction, both p-values rose to 0.16. By the field’s own conventions, neither finding is statistically significant.
The detail that matters most
The single most important sentence in this study is easy to miss in a list of statistics: the personality change observed in first-time psychedelic users was not clearly different from the change seen in first-time users of other illicit substances generally. That is the opposite of a psychedelic-specific effect. If openness rises and conscientiousness falls by a similar amount after someone’s first experience with any number of substances, the honest interpretation is not that psychedelics uniquely reshape personality. It is that trying something new, adopting a different lifestyle, or the kind of person likely to try an illicit substance for the first time in their twenties, all plausible explanations having nothing to do with pharmacology, are doing at least as much work as the drug.
One exploratory finding did survive: participants with a psychiatric diagnosis showed larger reductions in neuroticism after first use. The researchers frame this as exploratory and hypothesis-generating, which is the correct register for a subgroup finding in a study not designed or powered to test it. It is a lead for future controlled research, not a result to build a clinical claim on.
Why the naturalistic design cuts both ways
A study like this has real strengths the tightly controlled clinical trials don’t. It captures ordinary use, uncontrolled dosing, unsupervised settings, whatever the participant’s life circumstances happened to be, over a full year, in a sample more than ten times larger than most clinical psychedelic trials. That is a meaningfully different and complementary window onto the same question clinical research asks.
It also carries the limitation naturalistic designs always carry, and one the researchers built their statistical approach specifically to address rather than ignore: this is not a randomized comparison. People who choose to try a psychedelic for the first time differ from people who don’t, in ways a Big Five questionnaire and a list of covariates can only partly capture. The adjustment and multiple-comparison correction are exactly the right tools for this problem, and applying them honestly is what turned an apparently positive result into a null one. That the researchers ran the correction and reported the outcome plainly, rather than leading with the more publishable unadjusted numbers, is worth noting on its own.
Why this matters beyond one study
The durable openness increase is one of the more frequently cited findings supporting psychedelics’ broader personal-transformation narrative, the idea that a single guided experience can meaningfully and specifically reshape who someone is. That claim has always rested primarily on small, controlled clinical trials with supervised dosing, careful preparation, and structured integration therapy, a setting that bears limited resemblance to how psychedelics are actually used by most people who take them for the first time. This study is a reminder that clinical-trial effects and real-world effects are different questions, and that a genuine pharmacological signal in a tightly controlled clinical setting does not automatically predict what shows up when a large, ordinary population is followed honestly and analyzed correctly.
The frame
Nothing here overturns the clinical trial literature on psychedelics and openness, which used a different population, different dosing conditions, and different methodology, and remains its own evidence to weigh on its own terms. What this study adds is a caution against assuming that effect generalizes cleanly to everyday first-time use. A large, carefully analyzed naturalistic sample found a personality shift that looked, at first glance, like the famous clinical finding, and that shift did not survive rigorous statistical correction and was not specific to psychedelics once it was tested against other first-time drug use. For a field that has built part of its popular appeal on the promise of measurable personal transformation, a well-conducted study that mostly fails to find that transformation outside the clinic is exactly the kind of result worth taking seriously, not despite the null result, but because of the discipline it took to report one honestly.